A Randomized, Placebo-Controlled, Blinded, Crossover, Pilot Study of the Effects of Dextromethorphan/Quinidine for the Treatment of Neurobehavioral Symptoms in Adults with Autism.
J Autism Dev Disord
; 50(5): 1532-1538, 2020 May.
Article
em En
| MEDLINE
| ID: mdl-30109474
ABSTRACT
Prior studies have demonstrated successful irritability treatment using dopaminergic antagonists in autistic patients. The purpose of this pilot study was to assess the effect of dextromethorphan/quinidine (DM/Q) in autistic adults (18-60 years of age). This was a randomized, blinded, crossover, study of 14 patients randomized to DM/Q or a placebo for 8 weeks, washed out for 4 weeks, then crossed over to the opposite treatment. There were no serious adverse events. Subjects were significantly lower on the Aberrant Behavioral Checklist for Irritability (ABC-IR) (F1,10 = 7.42; p = 0.021). Improvements in aggression and Clinical Global Impression were also seen. The findings suggest that DM/Q is well-tolerated and associated with improvements in irritability and aggression in adults with autism.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Quinidina
/
Transtorno Autístico
/
Antagonistas de Dopamina
/
Dextrometorfano
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article